Many major histocompatibility complex (MHC) polymorphisms originate from ancient structures that predate speciation. As a consequence, members of the Mhc-DRB1*03 allelic lineage are not only present in humans but in chimpanzees and rhesus macaques as well. This emphasizes that Mhc-DRBl*03 members must have been present in a common ancestor of these primate species that lived about 30 million years ago. Due to the accumulation of genetic variation, however, alleles of the Mhc-DRBI*03 lineage exhibit species-unique sequences. To investigate the biological importance of such conservation and variation, we have studied both the binding and antigen presentation capacity of various trans-species Mhc-DRB1*03 lineage members. Here we show that p3-13 of the 65-kD heat-shock protein (hsp65) of Mycobacterium leprae and M. tuberculosis binds not only to HLA-DR17(3) but also to some chimpanzee and rhesus macaque class II-positive cells. Comparison of the corresponding human, chimpanzee, and rhesus macaque Mhc-DRBl*03 lineage members revealed the presence of uniquely shared amino acid residues, at positions 9-13 and 26-31, of the antigen-binding site that are critical for p3-13 binding. In addition it is shown that several nonhuman primate antigen-presenting cells that bind p3-13 can activate HLA-DR17-restricted T cells. Certain amino acid replacements, however, in Mhc-DRBl*03 lineage members did not influence peptide binding or T cell recognition. Therefore, these studies demonstrate that some polymorphic amino acid residues (motifs) within the antigen-binding site of MHC class II molecules that are crucial for peptide binding and recognition by the T cell receptor have been conserved for over 30 million years.
p eptides are able to bind to specificity pockets within the peptide-binding site of MHC molecules (1-3). The proposed model for the structure of MHC class II molecules (4) , which has been determined based on the resolution of the structure of HLA class I (5), shows that most polymorphic amino acid residues map within the peptide-binding site. Mhc polymorphism thus will result in the differential selection of peptides available for T cell recognition.
Mycobacterial heat-shock proteins (hsp) 1 are dominant T cell antigens in the response of healthy as well as mycobacterial disease-affected individuals (6) (7) (8) . The antigenicity of, but also the high homology between, several mammalian and bacterial hsp has led to the hypothesis that T cells initially 1 Abbreviations used in this paper: B-LCL, B lymphoblastoid call line; HA, hemagglutinin; hsp, heat-shock protein.
triggered by an infection may become crossreactive with selfpeptides. Eventually this results in, or may even prolong, autoimmune responses at local sites of inflammation (9) . The best characterized mycobacterial hsp is hsp65 (10) , which is recognized in the context of several different HLA-DR. molecules by CD4-positive, antigen-specific T cells (7, 8) .
Previously it was reported that hsp65 p3-13 is immunodominant in the mycobacterium-specific T cell response of HLA-DR17(3) -positive individuals and is not recognized in the context of any other HLA-DR molecule (11) . This DR17-restricted T cell recognition most probably arises from the fact that p3-13 binds to motifs uniquely present in HLA-DR17 molecules (12) .
Comparison of nucleotide sequences showed a high degree of similarity between some nonhuman primate Mhc alleles and certain HLA orthologs (13) (14) (15) (16) (17) . The degree of similarity between related Mhc class II alleles of different spe-cies is always higher than that found for alleles grouping in distinct lineages of the same species, as is consistent with the trans-species hypothesis (18) . This hypothesis states that closely related Mhc alleles in different species originate from common ancestral alleles, predating the divergence of these species. Trans-species alleles that group into a lineage are generally unique to a species due to the accumulation of genetic variation, mainly caused by point mutations or crossing over events (19) (20) (21) .
In this study we have investigated the functional importance of these conserved motifs that are present in the diverged members of the Mhc-DRB1 *03 aUelic lineage of humans, chimpanzees (Pan troglodytes), and rhesus macaques (Macaca mulatta). "['he capacity of different primate Mhc-DRBI*03 members to bind and present hsp65 p3-13 was analyzed using nonhuman primate-derived EBV-B lymphoblastoid cell lines (BLCL) as "biomutant" APC. As the corresponding nucleotide sequences of the Mhc-DRB molecules of these cells have been determined (20, 21) , it is now possible to pinpoint the essential Mhc-DRBI*O3-encoded residues involved in the binding of hsp65 p3-13. Moreover, the functionality of the p3-13 binding was analyzed in T cell stimulation assays using HLA-DR17-restricted, hsp65 p3-13-reactive human T cell clones and nonhuman primate-derived EBV-BLCL as APC.
Materials and Methods
Synthetic Peptides. Synthesis of p3-13 (KTIAYDEEARR) and p307-319 (PKYVKQNTLKLAT) has been described (12) . In short, peptides were made by standard solid-phase methods on a 10e10tide synthesizer using Fmoc amino acid pentafluorophenylesters (Cambridge Research Biochemicals Ltd., Cambridge, England). The long chain biotinylated analogues of the peptides were made by coupling of 6-(Fmoc amino) hexanoic acid and biotin (Serva, Heidelberg, Germany), respectively, at the end of the synthesis. The pe10-tides were purified by gelfiltration chromatography on a Sephadex G-25 (superfine) column (Pharmacia, Uppsala, Sweden) followed by reversed-phase HPLC (C18) purification, and analyzed by fast atom bombardment mass spectrometry.
Binding Assay. In the binding assay (12, 22) , EBV-BLCL (3 x 10S/sample) were incubated with the biotinylated peptide (50/~M) at 37~ for 4 or 20 h. As a control, cells were labeled in each experiment with a biotinylated mAb specific for HLA-DR (5/A; Becton Dickinson & Co., Mountain View, CA) at 4~ for 1 h. Peptide or anti-DR preincubation were followed by labeling with FITC-avidin D (10 #g/ml; 100 #1; Vector Labs, Burlingame, CA) at 4~ for 30 min. Incubation with FITC-avidin D was followed by incubation ofbiotinylated anti-avidin D (10 #g/ml; 100/A; Vector Labs) and FITC-avidin D again. After each incubation, excess reagents were washed off at 4~ using PBS containing 0.1% BSA. Stained cells were analyzed by flow cytometry on a FACScan | analyzer (Becton Dickinson & Co.). Dead cells were excluded from the analysis by propidium iodide staining. To measure the relative amount of FITC-avidin D bound, the mean fluorescence of 5,000 stained cells was determined. Background fluorescence, measured in the absence of peptide, was subtracted.
mAbs. The following mAbs were used in this study: anti-DR (B8.11.2); anti-class I (W6/32); anti--class II (1C2); anti-DQ (SPVL3); anti-DP (B7/21); anti-DR52 (7.3.19.1). All antibodies were used in a final concentration comparable with the ascites solution diluted 1:100 (in the binding assays) and 1:200 (in T cell proliferation assays). As a control, nonimmune mouse ascites were tested.
T Cell Proliferation Assays. Proliferation was assayed by mixing 104 T cells, irradiated DR-matched allogeneic PBMC (5 x 104/ well), or EBV-BLCL (3 x 104/we11) and antigen in 96-well fiatbottomed microtiter plates in triplicate. After 66 h of culture, 1 #Ci [3H]thymidine was added to each well, and 18 h later cells were collected on glass fiber strips, and the radioactivity incorporated into the DNA was determined by liquid scintillation counting. Mean and SEMs were computed from the cpm of triplicate tests.
Competition Experiments. Inhibition of activation of the HLA-DR17-restricted, p3-13-reactive T cell clone CAAp15 1-1 was studied in T cell proliferation assays by mixing 104 T cells, irradiated PBMC (5 x 104/we11), derived from rhesus macaques, stimulator peptide (10 ng/ml) and competitor peptide (final concentration: 0.1-, 1.0-, 10-, 100-and 1,000-fold excess relative to the stimulator pe10tide 103-13). Toxicity of competitor peptides, for either T cells or APC, was checked by mixing either T cells (104/well) and 10% IL-2 (Lymphocult-T; Biotest, Frankfurt, Germany) or PBMC (5 x 104/we11) and 0.5% PHA (Wellcome Diagnostics, Dartford, UK) with competitor peptide (final concentration, 10 #g/ml). To exclude the possibility that the nonresponsiveness to the competitor pe10tides was due to toxicity of those peptides for either the T cells or the APC, we tested the influence of these 10eptides on both the IL-2-dependent activation of the HLA-DR17-restricted T cells and the PHA-induced proliferation of the APC. The presence of the competitor pe10tides did not result in reduction of proliferation of the T cells nor did it disturb the activation by PHA. (20) , and Mamu-DRB (rhesus macaque) (21) sequences. The Mamu-DR specificities depicted in Fig. 1 were determined by serologic and RFLP techniques. For example, the DR1 specificity was determined by serology, and the A, B, C, and D designations that may follow represent subtypes defined by RFLP (24) . Alloantisera that recognize Patr-DR molecules are at present not available. The Patr-DR types of various chimpanzees that are shown in Fig. 1 have been determined by RFLP (25) . There is no obvious relationship between serologic HLA-DR specificities and serologically or RFLP-determined Patr-or Mamu-DR types, meaning that the nonhuman primate DR specificities have been named arbitrarily.
Nonhuman
The human homozygous typing EBV-BLCL used in this study are: OOS (HLA-DR1/Dwl), HAR (HLA-DR17, DR52a), and AVL (HLA-DR17, DR52a (11), since it selectively binds to (a pocket in) DR17 molecules (12) . It is anticipated that the presence of certain polymorphic amino acid residues (motifs) in the highly polymorphic DRB1 chain, situated in the MHC class II peptide binding site, is required for binding of p3-13 (13) . To measure the binding of p3-13 to different Mamu-DR and Patr-DR molecules, 11 different DR homozygous rhesus macaque and 11 disparate chimpanzee EBV-BLCL, selected for distinct DR specificities, were pulsed with biotinylated hsp65 p3-13. As a control for binding, the biotinylated analogue of the influenza HA peptide p307-319 (PKYVKQNTLKLAT) was used. This peptide is recognized by a HLA-DRl-restricted T cell clone (26) and is known to bind well to most or all HLA-DR molecules other than HLA-DR17 (22) .
The results of the binding experiments with the nonhuman primate BLCL are shown in Fig. I . For reference purposes the data for HLA-DR17-positive and -DR.l-positive BLCL, good binders for p3-13 and HA p307-319, respectively (12) , are also shown. For the chimpanzee-derived BLCL, binding of p3-13 is only found for cells with the Patr-DR13 specificity, whereas none of the other cell lines reach significant levels of binding (Fig. 1 A) . P3-13 binds to 3 of the 11 rhesus macaque cells tested with the specificities Mamu-DR1, -DR3C, and -DR9A (Fig. 1 B) . In contrast, HA p307-319 binds to all nonhuman EBV-BLCL tested, although the level of fluorescence varies (Fig. 1, C and D) . Fig. 2) . One would expect that the various p3-13 binding MHC-DRB chains share specific amino acid residues important for binding. As can be seen, all DR3 chains capable of binding p3-13 (Patr-DRBl*0308, Mamu-DRBI*0303, -DRBI*0305, and -DRBI*0306) share two motifs namely at positions 9-13 (EYSTS) and 26-31 (YL-DRYF), which therefore seem to be important for binding (Fig. 2) . These important motifs for p3-13 binding have been indicated in Fig. 3, depicting Fig. 2, and reference 12) . Circles represent amino acid residues that lie in the fl-pleated sheet; squares represent amino acid residues that are part of the a-helical structure of the molecule. (27) . In this light it was investigated whether, apart from the critical peptide-binding residues, polymorphic residues for T cell recognition had also been conserved in evolution. In that case, one would expect that T ceils that are selected to see p3-13 in the context of HLA-DR17 may recognize this peptide presented by some nonhuman equivalents that bind the peptide. To test this hypothesis the capacity of the BLCLs of 1WM (Mamu-DRBI*0303), 1KM (Mamu-DRB1 *0306), 1ZA (Mamu-DRBl *0305), and Victoria (Patr-DRB1 *0308), which all bind p3-13, to present the peptide to a HLA-DK17-restricted, p3-13-reactive T call clone, CAAp15 1-1, was analyzed in a T cell proliferation assay (Fig. 4) . As a positive control human PBMC (DK2,3) were used as APC. All APC were tested for presentation of hsp65 p418-427 to the hsp65-reactive, DK2-restricted T cell done K2F10 (28) . As a negative control rhesus macaque BLCL that did not bind p3-13 ( Fig. 1) , such as 1MC (Mamu-DRBl*0404) and 2849 (MamuDRBw8*0101), were used as APC as well. All BLCL derived from rhesus macaques that are able to bind p3-13 are also able to present the peptide to the p3-13-reactive human T cell done (Fig. 4) . Thus, the peptide not just binds to these cells but can also be presented by these nonhuman primate HLA-DR17-1ike alleles and give rise to T cell recognition and proliferation. BLCL of Victoria (Patr-DRB1*0308), however, are not able to present p3-13 to human T cells (Fig.  4) . This indicates that although the p3-13 binding residues are conserved in this chimpanzee-derived allde, the TCR contact residues or, alternatively, the conformation of the molecules have not remained the same. As expected, the nonbinding BLCL did not activate the T cells. None of the APC tested, except for the heterozygous human PBMC (DR2,3), were able to present the DR2-specific peptide, hsp65 p418-427, to the HLA-DK2-restricted human T cell clone K2F10.
Comparison of Mhc

Various differences between the primate MHC-DRB molecules that are able to bind p3-13, located at positions 32 (H--,.Y), 37 (N--~Y), 47 (F--~Y), 57 (D--~V,H), 60 (Y"~S), 61 (W--~Y), 67 (L--~Y,I), 68 (L--~V), 70 (Q---~D), 71 (K--~E,Q), 73 (G-*h), 74 (K--~A,S), 77 (N---,T), 78 (Y--~F), 84 (G-*R), and 86 (V--~G,A,C,F), do not
Specific Activation of HLA-DR17-restricted T Cells by p3-13 Presented by MHC-DR17-1ike Nonhuman
Inhibition of p3-13-mediated T Cell Activation of a HLA-DRI 7-restricted T Cell Line by mAbs.
To confirm the specificity of the binding of p3-13 to the rhesus macaque DR molecules, we coincubated p3-13 with either or-DR, c~-DP, c~-DQ, or-DR52, a-class I, or or-class II mAbs in T cell proliferation assays using either HLA-DR17-positive or Mamu-DKpositive EBV-BLCL as APC (Fig. 5) . Here, it is evident that binding of p3-13 is inhibited only by or-DR, or-DR52, and or-class II backbone mAbs. Thus, as expected, the presentation ofp3-13 is HLA-DRBI*03 restricted. The fact that the binding is also blocked by or-DR52 seems to be unexpected since 7.3.19.1 reacts with residue 73 (Gly) of DRB1, which is present on some Mhc-DRBI*03 and -DRB3 molecules (29) . Examination of the Mamu-DRB1*0305 allele, however, shows the absence of the epitope for 7.3.19.1 binding (Fig, 2) . Thus, in this particular case, T cell proliferation is probably inhibited by steric hindrance because mAb 7.3.19.1 binds to the MHC class II molecules of the human T cell, which does express the epitope in question.
Competition Experiments. Peptides with single amino acid substitutions, which are able to bind to MHC molecules, may not activate T cells (30) (31) (32) . Such competitor peptides of hsp65, p4-13, have been demonstrated to inhibit the HLA-DR17-restricted T cell response of p3-13-reactive T cell clones (33) . These peptides were now tested for their ability to inhibit the response of T cell clone CAAp15 1-1 to p3-13 in the context of rhesus macaque-derived PBMC. The results of the competition experiment are shown in Fig. 6 . P4-13 substituted at position 6 (A--~Q) was able to inhibit the response induced by p3-13. A control peptide, p4-13 (8D--P), which does not bind to HLA-DR17, was not able to inhibit the T cell response at all.
Discussion
Humans, chimpanzees, and rhesus macaques are primate species that share a progenitor that lived '~30 million yr ago (34) . The divergence between humans and chimpanzees took place •5-7 million yr ago (35) . Consequently, these closely related species may share highly similar immune systems. Sequencing studies have demonstrated that many MHC polymorphisms predate speciation, supporting the trans-species hypothesis (18) , and indicating that some of the polymor- competitor peptide (ng/ml) Figure 6 . Inhibition of hsp65 p3-13 (10 ng/ml) -stimulated activation of DR17-restricted T cell clone CAAp15 1-1 by a single amino acid substituted analogue of 1M-13. Inhibition peptide concentration is indicated on the x-axis. Proliferation is expressed on the y-axis (cpm). Stimulation index for competitor peptides without p4-13 were gl. Experience with nonhuman primate cells taught that proliferative responses using PBMC as APC are generally lower than when BLCL are used.
phisms are relatively old and represent stable structures. The finding that MHC class II polymorphism is maintained by strong selective forces (36) (37) (38) (39) implies that polymorphism must have some important function. The biologic significance of polymorphism observed within Mhc class II lineages was investigated by Mhc-peptide binding and T cell proliferation assays.
Here it is demonstrated that humans, chimpanzees, and rhesus macaques have particular Mhc-DRBl*03 lineage members in common. Only Mhc-DRBl*03 molecules that contain residues 9-13 (EYSTS) and 26-31 (YLDRYF) are able to bind p3-13. This indicates that at least two motifs are necessary for effective p3-13 binding (Fig. 2) . As can be seen, the absence of one of these motifs at 9-13 (EYSTS), as found in HLA-DRB3*0101, diminished p3-13 binding significantly. Apart from other residues, a critical residue for p3-13 binding is 26 (Y), as the substitutions at this position (Y--F) abrogates p3-13 binding (Fig. 2) . The presence of residue 26 (Y), however, is, on its own, not enough for p3-13 binding as is demonstrated by the lack of p3-13 binding for HLA-DRBI*0901, Patr-DRBl *0102, Mamu-DRBI *0402, and -DRB3 *0401.
The positively charged residues 71 (K) and 74 (R) are not present in other HLA alleles besides HLA-DRBI*03, and are supposed to be located in the peptide-binding site (4) . Therefore, it was proposed that these residues could contribute to p3-13 binding by interacting with the negative charge on the peptide (12) . However, by using nonhuman primate BLCL, we now demonstrate that p3-13 binding can occur also to Mhc alleles Patr-DRBl*0308 and Mamu-DRBl*0303, which lack positively charged residues such as 71 (K) and 74 (R,).
MHC molecules bearing the combination of 9-13 (EYSTS) and 26-31 (YLDRYF) motifs described above are present in human, chimpanzee, and rhesus macaque populations. This indicates that they may have been selected as polymorphic peptide contact residues (motifs) in the population in order to preserve binding of certain epitopes from important pathogens. Here one such combination is described. However, we envisage that other preferential MHC-peptide combinations may have been conserved within distinct primate species as well.
The reason for this interspecies conservation of class II motifs may have resulted from the fact that these related species can share the same pathogenic threats like mycobacterial infections (40) . Thus, some Mhc-DRB lineages, present in different primates, might have been maintained due to a selective advantage with regard to diseases, as described for HLA-B53 and severe malaria in West Africa (41) . This may also be the case for mycobacterial diseases, notably tuberculosis cases that have been described in nonhuman primates (42) . In addition, it has been reported that both chimpanzees (43) and rhesus macaques (44) can develop leprosy in experimental models, but even cases of naturally acquired leprosy in chimpanzees have been documented (45) . These examples emphasize that distinct but closely related species may suffer from shared pathogenic threats and diseases. Mycobacteria are important pathogens, and immunity against these pathogens is strictly T cell dependent both in healthy and in mycobacterial dis-ease-affected individuals (6) (7) (8) . P3-13 is the only peptide of hsp65 that is seen as a T cell epitope in HLA-DR17-positive individuals (11) . The conservation of a peptide-binding pocket for this immunodominant hsp65 peptide to primates of the Mhc-DRBI *03 lineage may reflect the importance of the T cell recognition of the peptide in the context of the same MHC molecules and the consequent survival of these species.
Nonhuman primate MHC molecules from rhesus macaques were not only able to bind p3-13 but also to present this peptide to HLA-DR17-restricted, p3-13-reactive human T cell clones (Fig. 4) . This indicates that p3-13 probably binds in the same conformation to nonhuman primate-derived BI.CL and that besides the Mhc-peptide binding residues, the Mhc-TCR contact residues have also been conserved. However, the chimpanzee allele that showed positive binding, Patr-DRBI*0308, could not present p3-13 to human T cells. This indicates that either p3-13 binding residues have been conserved in this allele and that the TCR contact residues have not, or that this peptide binds in a different conformation to the MHC molecule, which is not recognized by the TCR.
The B-pleated sheet and ol helix sections of the second domain of MHC class II molecules appear to have different evolutionary histories (17) . Especially, the B-pleated sheet-associated polymorphisms have been conserved between species whereas the ot helix accumulated considerably more variation (46) . The present data suggest that the B-pleated sheet section-encoded polymorphisms have been maintained in evolution because they encode motifs that are essential for the binding of some peptides needed to initiate an immune response. The ~ helix section of MHC class II molecules is probably recognized by the TCR. Since one individual encodes a high amount of different T cell receptors, the chance that nonresponsiveness is induced by amino acid replacements in the ot helix sections is relatively low. For that reason the ot helix is probably allowed to accumulate more variation than the ~-pleated sheet.
The conservation of MHC class II molecules for *30 million yr stands in contrast to the relatively fast evolution of some MHC class I molecules, as HLA-B antigens (47, 48) . This is may be due to the difference in origin of the antigens presented by either MHC class I or II molecules being endogenous and exogenous peptides, respectively. Since endogenous viral peptides change rapidly, the MHC class I molecules that present those peptides may have to adapt fast to avoid that, or such pathogens may escape CTL recognition. However, peptides derived from exogenous antigens are selected by MHC class II molecules after binding one of the polymorphic immunoglobulins on B cells and subsequent processing. Therefore, peptides with a more conserved nature can be selected to initiate antibody response, as is exemplified by the conservation of a peptide binding site for >30 million yr for the Mycobacterium-derived hsp65 p3-13. Furthermore, the p3-13 reactive T cell response of the HLA-DR17-restricted T cell clone CAAp15 1-1, which possesses the TCR VB1 segment, could be inhibited with specific, single amino acid substitution analogues of hsp65 p4-13 (33) using rhesus monkey--derived PBMC that were able to bind to p3-13 as APC. In this context it is relevant to note that not only the MHC may be highly similar in primate species but that equal observations may be done for other systems that are important for immune recognition. Recently, it was documented that rhesus macaques possess TCR V/31 segments that show 95.6 and 96% nucleotide similarity with their human equivalent (49). The observations described above demonstrate that human and nonhuman primate species share highly similar immune systems. As the HLA-DR3 allele is associated with several autoimmune and allergic diseases, such as SLE, celiac disease, insulin-dependent diabetes mellitus, and Graves' disease (50), the finding of comparable peptidepresenting capacity and specificity for certain nonhuman primate--derived APC could, therefore, open possibilities to study means of preventing HLA-DR3-associated diseases at a preclinical stage in experimental models of autoimmune disease in nonhuman primates.
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